Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2023-06-29 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
上海澄明则正律师事务所关于绿康生化股份有限公司2022年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 Annual General Meeting (AGM) of a company. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document includes specific voting outcomes on various proposals discussed at the AGM. It is not the AGM presentation materials themselves but a legal opinion related to the AGM. Given the content focuses on the AGM and its legal validation, the most appropriate classification is AGM Information (AGM-R). The document length and detail confirm it is not a brief announcement or a regulatory filing. Confidence is high due to the clear focus on AGM legal opinion and voting results.
2023-06-29 Chinese
上海澄明则正律师事务所关于绿康生化股份有限公司2023年员工持股计划（草案）的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2023 employee stock ownership plan (ESOP). It extensively discusses the legal compliance, procedures, and regulatory adherence related to the employee stock ownership plan, referencing relevant laws, regulatory guidelines, and company governance. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy solicitation. The document is a standalone legal opinion on a specific corporate action (employee stock ownership plan), which is a specialized legal and regulatory compliance report. This type of document fits best under the category of Regulatory Filings (RNS) as it is a compliance/legal opinion document that does not fit into other specific categories like Annual Report, Capital Update, or Proxy Solicitation. The document length is substantial and contains detailed legal analysis, not just a brief announcement or certification, so it is not RPA or a certification. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2023-06-25 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于绿康生化股份有限公司2023年员工持股计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2023 Employee Stock Ownership Plan (员工持股计划) of the company 绿康生化股份有限公司. It contains detailed sections including definitions, statements, assumptions, main content of the employee stock ownership plan, management mode, performance assessment, stock source, pricing, lock-up periods, and governance structure of the plan. The document is comprehensive and lengthy (15,000 characters), indicating it is the full report rather than a brief announcement. It is not an annual report, earnings release, or regulatory filing but a specialized advisory report on the employee stock ownership plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company financing activities through employee stock ownership plans and capital structure changes. Therefore, the appropriate classification is CAP with high confidence.
2023-06-25 Chinese
关于召开2022年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement about the convening of the 2022 Annual General Meeting (AGM) of the company 绿康生化股份有限公司. It includes information about the meeting date, agenda items to be voted on, voting procedures (both in-person and online), registration details, and proxy forms. The document does not contain financial statements or results but rather serves as a notice and instructions for shareholders regarding the AGM. It is not the actual Annual Report (10-K) or any financial report but a preparatory announcement for the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (5729 characters) and content confirm it is a full announcement rather than a brief report publication announcement or a regulatory filing.
2023-06-25 Chinese
绿康生化未来三年股东回报规划（2023-2025年）
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the years 2023-2025, including dividend distribution methods, decision procedures, and adjustment mechanisms. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is issued by the company's board of directors. The document is not a financial report, earnings release, or announcement of voting results, but rather a formal policy statement regarding dividends and shareholder returns. It is not a brief announcement or a certification letter, but a substantive policy document. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it details the company's dividend policy and plans for shareholder returns over a multi-year period.
2023-06-21 Chinese
绿康生化2023年度向特定对象发行A股股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票方案论证分析报告" which translates to "2023 Annual Report on the Proposal and Analysis of Private Placement of A-shares." It discusses the company's plan to issue A-shares to specific investors, including the background, purpose, legal compliance, pricing, and fairness of the issuance. It includes detailed financial analysis, regulatory references, and strategic rationale for the capital raising. The document is a comprehensive analysis report supporting a capital raising transaction through private placement of shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report publication, nor is it a full annual or interim report. It is not a proxy, voting result, or governance document. Therefore, the appropriate classification is CAP with high confidence.
2023-06-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.